(RTTNews) – Merck & Co., Inc. (MRK) said it has presented positive results from the phase 1/2 study, dubbed as V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, in pneumococcal vaccine
More Stories
Why Tesla Stock Is Soaring Today
Why Nuclear Stocks Are Glowing Green Today
Florida medical examiner releases cause of death for Louisville COVID-19 vaccine leader